Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms AMVISION-2
- Sponsors Amgen
- 26 Oct 2020 Primary endpoint (American College of Rheumatology (ACR) 20 Response) has been met according to the results published in the Annals of the Rheumatic Diseases
- 26 Oct 2020 Pooled analysis results from AMVISION-1 and AMVISION-2 studies were published in the Annals of the Rheumatic Diseases
- 09 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov